https://lgmpharma.com/product/umbralisib/
Umbralisib - LGM Pharma
umbralisiblgmpharma
https://ruixibiotech.com/pts/tgr-1202
TGR-1202 (Umbralisib) CAS:1532533-67-7 - Ruixibiotech
TGR-1202 (Umbralisib) CAS:1532533-67-7 - Umbralisib (TGR-1202, Rp-5264), a novel, next generation PI3Kδ inhibitor, inhibits PI3Kδ activity in enzyme and cell...
tgrumbralisibcas
https://www.onclive.com/view/fda-investigates-potential-increased-risk-of-death-with-umbralisib-in-select-lymphomas
FDA Investigates Potential Increased Risk of Death With Umbralisib in Select Lymphomas | OncLive
Oct 10, 2026 - The FDA has announced that they are investigating umbralisib (Ukoniq), an oral inhibitor of PI3K-delta and CK1-epsilon that is approved to treat patients with...
increased riskfdainvestigatespotentialdeath